



# MINDCURE

**A Full Cycle of Mental Wellness**  
**From Research to Remedy**

**CORPORATE PRESENTATION** SEPTEMBER 30, 2021

**CSE: MCUR | OTCQX: MCURF | FRA: 6MH**

# Disclaimer & Forward Looking Statements

This presentation (the “Presentation”) by MINDCURE Health Inc. (“MINDCURE”) is dated as of September 30, 2021. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities. This Presentation is not and under no circumstances is to be construed as a prospectus, offering memorandum, advertisement or public offering of any securities referred to herein, nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of MINDCURE are referred to the entire body of publicly disclosed information regarding MINDCURE. The information is subject to material updating, revision and further amendment, and is qualified entirely by reference to MINDCURE’s publicly disclosed information. This Presentation includes market and industry data and forecasts that have been obtained from third party sources, including industry publications. MINDCURE believes that the industry data and forecasts are generally reliable and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MINDCURE has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article. No representation or warranty, express or implied, is made or given by or on behalf of MINDCURE or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. MINDCURE does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice.

This Presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking information”) with respect to MINDCURE. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating and other plans as of the date of this Presentation but subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might”, or “will” be taken, occur or delivered. In this Presentation, forward-looking information includes, but is not limited to: statements pertaining to the research, development and commercialization of technology, intellectual property or related products, or the timing thereof; the likelihood of success of any

clinical trials; the likelihood of obtaining regulatory approval; the likelihood of obtaining patents or the efficacy of such patents once granted; the leadership team; the potential for the markets that MINDCURE is anticipating to access; and the factors described under the caption “Risk Factors” in MINDCURE’s annual information form dated August 31, 2021 and documents incorporated by reference therein, and other documents publicly filed by MINDCURE, which are available on MINDCURE’s profile at [www.sedar.com](http://www.sedar.com)

Forward-looking information is not a guarantee of future performance and is based upon a number of expectations, estimates and assumptions of management at the date the statements are made, including among other things, assumptions about: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; MINDCURE’s ability to raise capital to complete its plans and fund its studies and to raise additional capital as MINDCURE continues to develop its products; the medical and commercial viability of the contemplated products being developed; the continued availability of key leadership personnel; and, laws and regulations that affect MINDCURE’S business. While MINDCURE considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of MINDCURE and there is no assurance they will prove to be correct.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended. To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MINDCURE’s financial condition and its operational history and experience in the industry. Readers are cautioned that this information may not be appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All forward-looking information provided in this Presentation is qualified in its entirety by this cautionary statement, and MINDCURE disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Accordingly, readers should not place undue reliance on forward-looking information.

# MINDCURE

We are a life sciences company focused on developing **digital therapeutics technology** & **researching psychedelic compounds** to rapidly scale science-based and evidence-backed mental health therapy globally.





# Leadership Team

MINDCURE is led by a team of industry experts in biotech, life sciences, new product discovery, and technology.



## **Kelsey Ramsden – President & CEO**

15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. Built multiple 8-figure businesses and twice been named Canada's Top Female Entrepreneur. On the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. MBA from the Richard Ivey School of Business at the University of Western Ontario.



## **Dr. Joel Raskin – Chief Medical Officer**

Psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization with Eli Lilly & Co. Worked with medications for mood and anxiety disorders, schizophrenia, dementia, migraine and pain. As Senior Director, led medical affairs team for Alzheimer's Disease diagnostics and therapeutics. Medical degree and FRCPC Psychiatry from the University of Toronto.



## **Geoff Belair – Chief Technology Officer**

30 years of experience working in highly regulated industries, including fintech and banking. Senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Previously Vice President of Information Technology at Westland Insurance.



## **Tarik Lebbadi – Chief Operating Officer**

13 years of international operational experience. Led the medical division of Johnson & Johnson in Morocco. Holds a BA in Mathematics and Computer Science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.



## **Daniel Herrera – Vice President of Growth & Strategic Partnerships**

Pharmaceutical executive with extensive experience in highly regulated industries. Experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, and strategic partnerships resulting in high-value M&A transactions. Graduate of McGill University and the University of Montreal. MBA from the John Molson School of Business at Concordia University.



## **Michael Wolfe – Chief Financial Officer**

30 years' experience in finance, accounting, private equity, and business valuation. CFO of Baylin Technologies Inc. CFO of several mid-market Canadian companies, including Masstech Group Inc. General Partner at VenGrowth Capital Partners Inc. Has CPA, CA designation, a Chartered Business Valuator designation, an MBA from McMaster University, and a BA (Business and Economics) from the University of Western Ontario.

# Advisors

MINDCURE is supported by world-renown experts in neuroscience, mental health, pharmacology, and psychedelics.



## **Dr. Dan Engle, MD – Primary Investigator**

Medical degree from the University of Texas in San Antonio, psychiatry residency degree from the University of Colorado in Denver and Child and Adolescent Psychiatry Fellowship degree from Oregon Health and Sciences University. World-renowned for his specializations in psychiatry and neurology, with a background in integrative psychiatry, neurocognitive restoration, peak performance medicine and psychedelic research.



## **Hamilton Morris – Scientific Advisor**

A chemist, filmmaker, and science journalist. The director of the award-winning documentary series Hamilton's Pharmacopeia. Attended the University of Chicago and The New School in New York City. Frequently consults with media on the subject of psychoactive drugs and conducts pharmacological research at the University of the Sciences in Philadelphia.



## **Dr. Jason Wallach, PhD – Scientific Advisor**

Instructor in the Department of Pharmaceutical Sciences as well as the Substance Use Disorders Institute at the University of the Sciences, Philadelphia, Holds an adjunct appointment at Cooper Medical School of Rowan University, Camden, NJ. Author of over 20 publications in peer-reviewed journal articles. PhD in Pharmacology and Toxicology from University of the Sciences. BS in Cell and Molecular Biology from Indiana University of Pennsylvania.



## **Dr. Wolfram Tetzlaff, MD, PhD – Scientific Advisor**

Director of ICORD and a professor in the departments of Zoology and Surgery at the University of British Columbia. Holds John and Penny Ryan British Columbia Leadership Chair in Spinal Cord Research. MD at the University of Essen, his Dr. Med. at Ruhr-University Bochum. PhD at the University of Calgary.



## **Hector MacKay-Dunn, Q.C. – Advisor**

30 years of experience providing legal advice to high growth public and private companies in life sciences, health, mining, clean tech. Advises on corporate domestic & cross-border public & private security offerings, M&A, international partnering & licensing transactions, and board committees on corporate governance. Recognized by Lexpert as being among the Top 100 Canada/US Cross-Border Corporate Lawyers in Canada and Leading 500 Lawyers in Canada; by Best Lawyers as Lawyer of the Year 2020 in Biotech and a Leading Lawyer in M&A, tech, corporate & securities; and in Chambers Canada 2020.



## **Dr. John Brownstein – Scientific Advisor**

Chief Innovation Officer of Boston Children's Hospital and Professor of Biomedical Informatics at Harvard Medical School. Directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children's. Trained as an epidemiologist at Yale University. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU. Serves advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House.

# Board Members



## **Philip Tapley** – Chairman of the Board of Directors

25 years of experience driving transformational change in highly regulated industries. Most recently Chief Information Officer at Westland Insurance. Founded iProcess Solutions, a pioneer in the insurance technology space. MBA from Simon Fraser University.




## **Larissa Chaikowsky** – Director

Chief Operating Officer for the U.S. Wealth Management business at BMO. Previously the U.S. Chief Human Resources Officer for BMO Financial Group. At BMO, has held several senior positions, helping redefine the BMO brand and improving the business practices of Technology and Operations, Human Resources and Corporate Strategy. Bachelor's of International Business and Relations from the Sprott School of Business at Carleton University. MBA from the Richard Ivey School of Business.



## **Kelsey Ramsden** – President & CEO

15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. Built multiple 8-figure businesses and twice been named Canada's Top Female Entrepreneur. On the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. MBA from the Richard Ivey School of Business at the University of Western Ontario.



## **Robert C. Hill** – Director

Managed private and publicly traded cannabis, technology, and financial services companies in Canada, the USA, and Japan. CPA designation in British Columbia, Canada. Began career with KPMG, served as VP at Haywood Securities, and most recently a CFO in the Technology and Media and Life Sciences industries.



## **Jason Pamer** – Director

20 years of experience managing operations and product development in the technology and consumer products industries. Led start-up companies through concept to launch and has also managed strategy and development at large enterprise software companies. Led e-commerce operations across digital media, health and medical cannabis. MBA from Simon Fraser University.

# Mental Wellness: The Mental Health Epidemic


There is a critical need for effective mental health treatment options.



24% of adults report unmet need for mental health treatment.<sup>1</sup>



40% of US adults struggle with mental health or substance abuse.<sup>2</sup>



During the pandemic, 41% of adults reported symptoms of anxiety and/or depressive disorder and 11% reported thoughts of suicide in the past 30 days.<sup>3</sup>

Workplace mental health problems cost employers an estimated **\$500 billion** annually of lost productivity.<sup>4</sup>

1. <https://www.mhanational.org/issues/state-mental-health-america>


2. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6932a1.htm>

3. <https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/#:~:text=During%20the%20COVID%2D19%20pandemic,largely%20stable%20since%20spring%202020.>

4. <https://mhanational.org/sites/default/files/Mind%20the%20Workplace%20-%20MHA%20Workplace%20Health%20Survey%202017%20FINAL.pdf>




## Psychedelics show promise in treating a variety of mental health conditions.




## MDMA

In MAPS' completed Phase 3 trial, 67% of participants no longer had PTSD after three treatment sessions.<sup>1</sup>




## KETAMINE

A double-blind placebo-controlled study confirmed significant therapeutic improvements as early as 80 minutes after a single dose of ketamine.<sup>2</sup>



## PSILOCYBIN

In one study using psilocybin, 54% of participants were considered in remission from major depressive disorder four weeks post-treatment.<sup>3</sup>



# IBOGAINE

A single ibogaine treatment reduced opioid withdrawal symptoms and achieved opioid cessation or sustained reduced use in dependent individuals as measured over 12 months.<sup>4</sup>

1. <https://www.nature.com/articles/s41591-021-01336-3>

2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353120/>


3. <https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows>

4. <https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218>



# MINDCURE: Uniquely Positioned

- By concentrating on both **technology** and **research**, MINDCURE is focusing on near-term revenue, a longer-term blue sky horizon, and hedges against regulatory unknowns with a globally scalable, adaptive model.
- **Our SaaS platform** scales globally, servicing every psychedelic medicine, without the capital intensive drag of clinic scale-out costs.
- **Our beachhead is psychedelic-assisted psychotherapy**, then on to larger penetration fields of technologically un-disrupted psychotherapy and psychiatry.



# Our Technology




# Technology: Opportunity

**Digital therapeutics (DTx) are health interventions delivered through a smart device to induce a behavioral change in the patient.**

- Global DTx is projected to reach **USD \$6.9B** by 2025, from **\$2.1B** in 2020<sup>1</sup>
- DTx in North America is projected to reach **USD \$5.0 billion** by 2025<sup>1</sup>
- Giants in global market focused on simplifying behavioral change and empowering consumers to take charge of their own health:

| COMPANY        | VALUE                   | SPACE                 |
|----------------|-------------------------|-----------------------|
| Noom           | Revenue \$237 million   | Weight loss           |
| Livongo Health | Valuation \$37 billion  | Hypertension/Diabetes |
| Omada          | Valuation \$600 million | Chronic Disease       |




**MINDCURE's iSTRYM proposes this consumer-focused mindset in its technology platform with a B2B2C Model – allowing for greater market capture. SaMD approval by the FDA would unlock insurance payer model.**

1. Data sources from Markets and Markets' "Digital Therapeutics (DTx) Market – Global Forecast to 2025 Report".

# Technology: Digital Therapeutics (DTx)

## iSTRYM Mental Health DTx



**AI-driven mental health patient lifecycle platform  
from assessment to monitoring = reducing costs & improving outcomes**

### PRECISION MEDICINE & QUANTIFIED THERAPY

#### Onboarding & Assessment Tool Kit

Captures powerful data with Speak Ai and wearables. Takes assessment data, centralizes it, and organizes it. Orients to applicable care options.

#### Therapeutic Protocol Catalogue

Therapy and medicine protocols, generate and optimize custom treatment plans.

#### In Session Assets for Optimization

Proprietary music tool and biometric monitoring allows real-time adjustment control based on in-session feedback.

#### Ritual Suite

Optimize and personalize outcomes with spiritual and science-backed daily practices. Tap into the transformative power of music, breathwork, and visualization.

#### AI Driven Analysis Engine


AI Analysis and Assessment constantly driving optimization and recommendations, generating new insights for patient, therapist and researchers.



# Technology: iSTRYM for the Therapist




Katherine - Practitioner



- **Modernizes care from manual to digital**, yielding better outcomes and cost savings for therapists and insurers
- **Provides a distribution network of science-based protocols** from psychedelic companies directly to therapists
- **Expands therapists' toolkit for gold standard care** with assessments, propriety AI-driven music and more
- **Monitors biometrics and psychometrics**, providing reliable data for timely interventions and care optimization
- **Supports post-session integration and connectivity** through a suite of science-backed tools
- **Delivers optimized protocols and proof of efficacy** at scale, creating a competitive advantage for therapists

**DEEPER DATA, BETTER CARE, REDUCED COSTS  
& BETTER OUTCOMES.**

# Technology: iSTRYM for the Patient



**Josh - Patient**


“The old pen and paper therapist can’t give me what I need to understand and take control of my mental health. I want to know what I need to do, when I need to do it, and how it’s helping at each step. I want my journey to be personalized and modernized.”

- **Modernizes care from manual to digital**, catering to the trend towards digital interfaces
- **Provides data-backed assurances for patients** who are cautious about using psychedelic therapies
- **Expands toolkit of specific and actionable insights**, elevating patient to colleague in care
- **Connects patients with therapists** and emergency services 24 hours a day, 7 days a week
- **Personalizes care and provides optimization** for each patient’s unique goals and mental health journey
- **Promotes daily rituals post-care**, promoting a continuation of the client’s journey to optimized mental wealth

**IMPROVING COMPLIANCE, OPTIMIZING OUTCOMES  
& PROOFING SAFETY AND EFFICACY.**

# Technology: Market Opportunity/Timeline


- **Launch iSTRYM** as backbone for psychedelic-assisted psychotherapy clinics.
- Once established, **iSTRYM to be utilized more broadly** by not only psychedelic-assisted psychotherapy clinics but also integrated clinics that offer psychedelic-assisted psychotherapy and general mental health service providers.
- **620,000 mental health professionals in the USA serving 1 in 5 adults, or 65 million Americans**, who suffer from mental health issues. There's a growing need for technology to scale practices as mental health issues continue to rise, allowing for greater billing and access to care.<sup>1</sup>



1. [https://www.apna.org/files/public/Resources/Expanding\\_Mental\\_Health\\_Care\\_Services\\_in\\_America-The\\_Pivotal\\_Role\\_of\\_Psychiatric-Mental\\_Health\\_Nurses\\_04\\_19.pdf](https://www.apna.org/files/public/Resources/Expanding_Mental_Health_Care_Services_in_America-The_Pivotal_Role_of_Psychiatric-Mental_Health_Nurses_04_19.pdf)

# Technology: Scale Model

- We've set our sights on being the **distribution network for care protocols** (psychedelic and integrative), the trusted tool of therapists, and the trusted provider of the quantified mind for individuals.
- Our platform is designed to benefit from a **double network effect**, grow exponentially, and create a barrier to entry.






# Technology: Path to Revenue

**MINDCURE**'s goal is to be the leader in science-based, evidence-backed clinical digital therapeutics in the psychedelic-assisted psychotherapy space.

**iSTRYM** is a **first-of-its-kind software as a service** (SaaS) designed to support clinicians in the daily management of practice and patients, and importantly, improve the health outcomes of clinics around the world.

| 2021   |   |                                 |   | 2022   |   |
|--|---|---------------------------------|---|--|---|
| Q1   | Q2  | Q3                              | Q4  | Q1 - Q2  | Q3 - Q4                                   |
| ✓ Pre-development market analysis and strategic assessment | ✓ Development of minimum viable product (MVP)<br>✓ Biometric data integration<br>✓ Artificial Intelligence (AI) development | ✓ MVP launch and market testing | MVP expansion into 10 clinics in Canada and USA | Commercial product launch of iSTRYM<br><br>Target of 75 clinics in Canada and USA<br><br>Pre-submission meeting regarding SaMD | Target 150 clinics in Canada, USA, and UK |

# Our Research



# Research: The Desire Project – Overview

## Using MDMA-Assisted Psychotherapy to Help Women Overcome Lack of Desire

**Hypoactive Sexual Desire Disorder (HSDD)** is a common female sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue<sup>1</sup>.

### OPPORTUNITY:

- **40%** of US women self-report that they have low desire<sup>2</sup>
- HSDD affects **10%** of adult women<sup>2</sup> and **14%** of premenopausal adult women<sup>3</sup>, all reporting that their low desire results in a state of distress
- In the U.S. alone, HSDD affects an estimated **9.5 million premenopausal women**<sup>4</sup>
- A highly under researched and under treated area of mental health care
- The two FDA-approved drugs designed to treat loss of sexual desire in females **only treat the symptoms**, rather than the underlying causes
- We have an opportunity to find a **more effective and better tolerated treatment** for women affected by this disorder
- The Desire Project brings together a **team of experts** in sexual disorders and psychedelics to drive clinical outcomes for female Hypoactive Sexual Desire Disorder (HSDD)

1. <https://pubmed.ncbi.nlm.nih.gov/27872021/>

2. <https://pubmed.ncbi.nlm.nih.gov/27916394/>

3. [https://journals.lww.com/greenjournal/Abstract/2018/05001/Incidence\\_and\\_Knowledge\\_of\\_Hypoactive\\_Sexual.649.aspx](https://journals.lww.com/greenjournal/Abstract/2018/05001/Incidence_and_Knowledge_of_Hypoactive_Sexual.649.aspx)

4. Based on an estimate of the number of premenopausal women in the U.S and the expected number of women affected by HSDD (see footnote 2 above)

# Research: The Desire Project – Solution

## Exploring the potential of MDMA for Desire in a Clinical Study


With the Desire Project, we're developing a safe and evidence-based research environment with an optimal setting in order to examine the causes of HSDD in order to develop a solution using pharmaceutical MDMA and psychotherapy.

### THE POTENTIAL

- **MDMA** with psychotherapy has been shown to help people heal from **Post Traumatic Stress Disorder (PTSD)**. It is also showing promise in other mental health related challenges
- Studies show that MDMA allows one to **open up and work through tough challenges** that would otherwise be difficult to address. Desire is considered **a product of the mind** and we believe that MDMA can treat the root causes of HSDD which are often linked to **trauma or negative experiences**
- MDMA has been reported to increase **sexual desire and satisfaction**<sup>2</sup>

### REASON TO BELIEVE:

- We have identified **a gap in the market** to help women seeking improved desire
- We are Developing a clinical study combining pharmaceutical **MDMA and psychotherapy**
- MINDCURE is working with **leading experts** in the fields of sexual health and psychedelics
- We are using molecules that will be **first to market** - MDMA is predicted to be approved by 2023<sup>1</sup>



1. <https://www.maps.org/research/mdma>  
2. Zemishlany Z, Aizenberg D, Weizman A, Subjective effects of MDMA ('Ecstasy') on human sexual function, Eur Psychiatry 2001 ;16:127-30.



# Research: The Desire Project – Team

Led by Dr. Joel Raskin (CMO), MINDCURE's Desire Project research team is comprised of some of the most well-cited researchers in female sexual desire, as well as the lead author of the MAPS MDMA for PTSD study.



## Dr. Anita H. Clayton, MD

Professor & Chair of the Department of Psychiatry & Neurobehavioral Sciences and Professor of Clinical Obstetrics & Gynecology at the University of Virginia. Associate Member of the American College of Obstetrics & Gynecology. Founding faculty in the UVA Women's Midlife Health Center. Principal Investigator on numerous research grants and involvement in developing sexual medicine nomenclature for ISSWSH, ICSM, and WHO/ICD-11. A research career focused on sexual medicine and women's mental health including mood disorders associated with reproductive-life events, treatment-resistant depression, clinical trials of new treatment paradigms, sexual dysfunction related to illness and medications, and treatment of primary sexual dysfunctions in women.



## Dr. Jennifer M. Mitchell, PhD

Neuroscientist focused on innovation in the treatment of addiction and other mental health issues including PTSD, anxiety, depression, and impulsivity. She is currently conducting research for MAPS in their quest to test and develop MDMA as a treatment for PTSD. A Professor in the Departments of Neurology and Psychiatry at UCSF, her research group studies the mechanisms of expression of behavioral disorders through the use of translational tools to identify new potential treatments. PhD in Neuroscience from UCSF, extensive and diverse experience with human and animal pharmacology, hypothesis-driven neuroscience, human proof-of-concept studies & clinical trials.



## Dr. Cindy M. Meston, PhD

Full Professor of Clinical Psychology at the University of Texas at Austin. Directs the Female Sexual Psychophysiology Laboratory to study women's sexual health from both a psychological and physiological perspective. Past President of ISSWSH and an active member of IASR. Named one of the 100 most influential and inspirational women in the world by the BBC, London, England in 2016. PhD in Clinical Psychology from the University of British Columbia. Postdoctoral fellowship in Sexual and Reproductive Medicine at the University of Washington, School of Medicine. Postdoctoral fellowship from the Social Science Research Council, Ford Foundation, NY.



## Dr. Robert E. Pyke, PhD

Worked for four major and seven smaller pharma companies including Bristol Meyers, contributing to 6 NDAs or SNDAs on AIDS, anxiety, depression, insomnia, spasticity, analgesia, and sexual dysfunction. Directed a Phase I clinic & a drug dependence clinic. Served as clinical investigator for three antidepressants. Led the Addyi® project through Phases II and III, helped develop the currently accepted measures and diagnostic interviews, brought Lorexys® through IND and Phase 2a, and has over 100 peer-reviewed publications in the last 18 years. PhD in Internal Medicine from the University of Miami and PhD in Biochemistry from the University of Wisconsin.



## Dr. Sherry Walling, PhD

Clinical psychologist, theologian, best-selling author, yoga teacher, & mental health advocate specializing in trauma, stress, burnout, spirituality, & mind-body integrated treatment. Published researcher in academic journals including the Journal of Traumatic Stress. Graduate of the University of California, Davis and Fuller School of Psychology. PhD in clinical psychology & Master's Degrees in both psychology & theology. Pre-doctoral research fellowship in prevention & community research at Yale University School of Medicine. Post-doctoral fellowship at the National Center for PTSD in Boston. Trained in ketamine-assisted psychotherapy with the Psychedelic Somatic Institute, currently training in the MAPS MDMA treatment protocol for PTSD.

# Research: Ibogaine – A Growing Need

Potential therapeutic uses of ibogaine from preliminary data include:

## Addiction

the drug, alcohol and other addictions treatment industry will be worth **\$38.2 billion this year** (5.2% annual growth in revenues)<sup>1</sup>

## Neuropathic Pain

the global neuropathic pain market is estimated to account for **US\$ 9.0 billion by the end of 2027**<sup>2</sup>

## Migraines

the global migraine drugs market was valued at **\$1.7 billion in 2017** and is expected to reach **\$2.1 billion by 2025**

- Inaccessibility to a reliable supply of pharmaceutical grade ibogaine **limits opportunities for research, product, and protocol development.**
- The need for ibogaine in research and therapeutic settings **is expected to grow vastly over the years** as scientists investigate and discover further indications.
- One such indication is **Traumatic Brain Injury**. Anecdotal evidence supporting ibogaine has a positive effect on TBI and suggests support for further research in using ibogaine to treat TBI. We are not the only ones who think so.<sup>4</sup>

1. <https://blog.marketresearch.com/38-billion-u.s.-addiction-rehab-industry-pivots-to-cope-during-covid-19-pandemic>  
2. <https://www.globenewswire.com/news-release/2020/05/25/2038154/0/en/Neuropathic-Pain-Market-to-reach-US-9-862-3-Million-globally-by-2027-Coherent-Market-Insights.html>  
3. <https://www.alliedmarketresearch.com/migraine-drugs-market>  
4. <https://clinicaltrials.gov/ct2/show/NCT04313712>

# Research: Ibogaine – Synthesis


## Why Ibogaine Synthesis Matters

- **TO CREATE AN ENVIRONMENTALLY-FRIENDLY & SUSTAINABLE SUPPLY.**

As a leader in psychedelics, MINDCURE recognizes the value of the iboga plant as a rare and diminishing resource.

- **TO PROVIDE AN OPPORTUNITY FOR PSYCHEDELICS RESEARCHERS.**

By synthesizing pharmaceutical grade ibogaine, we are creating the opportunity for the use of a sustainable, high-quality, and regulated supply to be used by researchers conducting clinical trials, and eventually, by clinicians providing psychedelic therapy.



# Research: Summary

- USING MDMA-ASSISTED PSYCHOTHERAPY TO HELP WOMEN OVERCOME LACK OF DESIRE
- MANUFACTURING PHARMACEUTICAL GRADE IBOGAINE
- PRECLINICAL RESEARCH WITH PSYCHEDELIC COMPOUNDS FOR TBI AND OTHER INDICATIONS THAT MAY INVOLVE MOOD





# Investment Summary




# Company: Catalysts & Milestones

| Q1-Q2 2021  | Q3-Q4 2021  | Q1-Q2 2022  |
|---|---|---|
| <p><b>iSTRYM</b></p> <ul style="list-style-type: none"> <li>✓ Confirm the beta deployment partnership with ATMA for psychedelic therapy patient data collection</li> <li>✓ Initiate partnership with unstructured data AI engine to integrate into iSTRYM™</li> <li>✓ iSTRYM: integrating biometric data and developing AI to drive integration protocol optimization</li> <li>✓ Patent filing on proprietary digital therapeutics platform</li> </ul> <p><b>RESEARCH</b></p> <ul style="list-style-type: none"> <li>✓ Primary investigator secured for our first psychedelic research program</li> <li>✓ Research relationship secured for our second psychedelic program</li> </ul> | <p><b>iSTRYM</b></p> <ul style="list-style-type: none"> <li>✓ iSTRYM™ fully functional beta deployment into multiple psychedelic treatment facilities</li> <li>✓ Update on psychedelic research clinic partnerships with iSTRYM™</li> </ul> <p><b>RESEARCH</b></p> <ul style="list-style-type: none"> <li>✓ Patent applications for company's first fully synthetic routes to create ibogaine</li> <li>✓ Non-GMP scale up on the iboga molecule</li> <li>✓ Initiate major research program</li> </ul> | <p><b>iSTRYM</b></p> <ul style="list-style-type: none"> <li>● Commercial product launch for iSTRYM with target of 75 clinics in Canada and USA</li> </ul> <p><b>RESEARCH</b></p> <ul style="list-style-type: none"> <li>● Schedule pre-IND meeting with FDA for Desire Project</li> <li>● Ketamine-enhanced psychotherapy protocol for undisclosed indication developed and distributed through iSTRYM</li> <li>● Pre-submission meeting regarding SaMD for iSTRYM</li> <li>● Update on new molecular entity</li> </ul> |



Accomplished per plan

# Partnerships



MINDCURE is licencing SOMA's 21-day mental health-designed breathwork program and building a custom breathwork track targeted towards iSTRYM and psychedelic-assisted psychotherapies.



MINDCURE has strategically invested in ATMA. Their established clinical footprint provides an initial opportunity to deploy iSTRYM, optimize treatment for their patients, and obtain the data required to build iSTRYM into the platform trusted by therapists and patients around the world.



LUCID's mission is to help people optimize their mental wellness through music. We are utilizing LUCID's machine learning systems to design custom psychedelic music experiences for iSTRYM.



Partnering with Speak Ai will drive data for iSTRYM, taking unstructured data and creating structure and metrics for the platform integration.

# Share Information & Capital Structure

TRADING SYMBOL: CA ..... CSE: MCUR

TRADING SYMBOL: US ..... OTCQX: MCURF

TRADING SYMBOL: FRANKFURT ..... FRA: 6MH

SHARES OUTSTANDING ..... 93.7M

OPTIONS OUTSTANDING ..... 10.2M

WARRANTS OUTSTANDING ..... 29.7M

FULLY DILUTED ..... 133.6M

AVERAGE DAILY VOLUME TRADED (OVER 90 DAYS) ..... 0.7M

MANAGEMENT / INSIDER OWNERSHIP ..... 8.2%

CASH POSITION ..... \$18.3M

*As of May 31, 2021. All figures are noted in Canadian dollars.*

SHARE PRICE ..... \$0.34

52 WEEK HIGH/LOW ..... \$1.09 / \$0.31

MARKET CAPITALIZATION ..... \$31.9 M

*As of September 15, 2021. All figures are noted in Canadian dollars.*

## MINDCURE HEALTH INC. (CSE:MCUR) SHARE PRICE





# Why Invest Now




**Proprietary  
digital  
therapeutics**



**Clear path  
to near-term  
revenues**



**World-class  
scientific  
discovery team**



**Strong  
financial  
position**



# MINDCURE

[info@mindcure.com](mailto:info@mindcure.com)

[investors@mindcure.com](mailto:investors@mindcure.com)

[www.mindcure.com](http://www.mindcure.com)

+1.888.593.8995

